Biomarkers for Detecting and Monitoring Aortic Aneurysms


The inventors have developed a highly specific and sensitive panel of biomarkers, including various matrix metalloproteinases (MMPs) and tissue inhibitor matrix metalloproteinases (TIMPs), which identifies and follows the progression of thoracic aortic aneurysm in patients. These biomarkers can be detected and measured by performing a simple, point-of-care blood test and provide earlier detection than the current diagnostic tests.




Thoracic aneurysms affect approximately 15,000 people in the United States each year. The incidence of TAA is projected to increase significantly in prevalence with the “Baby Boomer” generation. Aneurysms develop gradually over many years. Most patients have no symptoms until the aneurysm begins to leak or expand. Furthermore, most asymptomatic patients are often diagnosed with TAA on examinations for other complaints. The survival rate of hospitalized patients with a ruptured TAA is usually less than 20 to 30 percent. Annual surveillance methods, including CT scanning and MRI studies pose additional risks to patients or are not widely accessible due to high cost. There is a growing, unmet need for early diagnosis of patients with TAA, as this can improve patient outcomes resulting in reduced cost for hospitals, a reduction in mortality rate among TAA patients, and increased patient access.


Early identification and monitoring of patients at risk for thoracic aortic aneurysm


Key Words: Aortic aneurysm, hypertension, diagnostic


Publications: Ikonomidis , John S., et al. "Regulation of membrane type-1 matrix metalloproteinase activity and intracellular localization in clinical thoracic aortic aneurysms." The Journal of Thoracic and Cardiovascular Surgery (2016).

Ikonomidis, John S., et al. "Plasma biomarkers for distinguishing etiologic subtypes of thoracic aortic aneurysm disease." The Journal of thoracic and cardiovascular surgery (2013).


Inventors:                               J.S. Ikonomidis, J.A. Jones, R. Mukherjee

Patent Status:                        US Utility Application Filed 12/24/2014
MUSC-FRD Technology ID:    P1267

Patent Information:
For Information, Contact:
Troy Huth
Sr Licensing Manager
MUSC Foundation for Research Development
John Ikonomidis
Jeffrey Jones
Rupak Mukherjee
Robert Stroud
Michael Zile
© 2018. All Rights Reserved. Powered by Inteum